



Co-funded by the European Union  
Grant Agreement n° 874719

## **EU Onco-Platform Lot 3/ Lot 4** (Lead: BC Platforms AG)



### **Project abstract**

BC Platforms, Euformatics and Oncompass Medicine have decided to form a consortium with us leading European SMEs that together represent the state of the art and beyond for functionality corresponding to Lots 3+4. We will supplement this with new innovations for the project, meeting and exceeding the requirements. The three companies are BC Platforms (BCP), Euformatics (EUF) (both with R&D operations in Finland) and Oncompass Medicine (OCM) with R&D operation in Hungary. The Tender identifier "EU ONCO-PLATFORM" is meant to reflect all three companies (EUformatics-ONCOMPASS-BC PLATFORMS). Our consortium members participate in a joint tender with close collaboration for both Lot 3 and Lot 4 with BCP being the lead tenderer having marketed solutions for workflow automation and products that are CE marked as medical devices and will comply with CE-IVDR that span over both Lots 3 & 4. We foresee a very tight integration between Lot 3+4 given that we would be selected for both. However, we have also taken into consideration that the Lots are evaluated separately and hence we follow the guidelines provided in Q&A documents regarding the interfaces between the Lots so they can be evaluated separately and function each by themselves.

In Lot 3 our consortium possesses tools already meeting many requirements of the NGS4P RfT Lot3 in terms of technical and user needs. BC Platforms' BC|GENOME, Euformatics' omnomicsQ, omnomicsV and omnomicsNGS are existing software solutions, already providing many of the requested features and resources, readily available for further development based on the needs outlined by the Buyer's group. The planned innovations will add novel features and modules to a base of already existing tools.

In Lot 4, EU Onco-Platform provides a unique opportunity to realise precision oncology at and beyond state of the art in terms of reporting and e-medication. Our consortium is the only one so far, which has a validated, rule-based decision support system for digital drug-assignment of targeted therapies to entire molecular profiles, also capable of integrating other structured data requested by the Buyers Group. All members have years of experience in clinical

reporting of NGS results, and there is a significant synergy among the members with different backgrounds and business areas. Proven by the pre-existing reporting tools, all members are capable of innovating and meeting patients' and carers' needs in terms of reporting NGS results.